Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine versus sufentanil plus propofol for anesthesia in ERCP
ChiCTR2400086623Phase 4Not yet recruiting
- Sponsor
- Huizhou Third People's Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oliceridine, sufentanil and propofol in endoscopic retrograde cholangiopancreatography (ERCP) (2 arms), sponsored by Huizhou Third People's Hospital. Primary endpoint: Incidence of hypoxemia. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
oliceridinesufentanilpropofol
03
Conditions
endoscopic retrograde cholangiopancreatography (ERCP)
Beyond the preview
Go deeper on ChiCTR2400086623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086623.